

▼ This medicinal product is subject to additional monitoring in Australia. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse events at www.tga.gov.au/reporting-problems.

AUSTRALIAN PRODUCT INFORMATION

OMJJARA (mometotinib) film-coated tablets

1 NAME OF THE MEDICINE

Mometotinib dihydrochloride monohydrate

2 QUALITATIVE AND QUANTITATIVE COMPOSITION

Each film-coated tablet contains 100 mg, 150 mg or 200 mg of momelotinib as momelotinib dihydrochloride monohydrate.

List of excipients with known effect

Lactose

For the full list of excipients, see Section 6.1 LIST OF EXCIPIENTS.

3 PHARMACEUTICAL FORM

OMJJARA 100 mg film-coated tablets

Brown, round tablets, with an underlined “M” debossed on one side and “100” on the other side.

OMJJARA 150 mg film-coated tablets

Brown, triangle shaped tablets, with an underlined “M” debossed on one side and “150” on the other side.

OMJJARA 200 mg film-coated tablets

Brown, capsule shaped tablets, with an underlined “M” debossed on one side and “200” on the other side.

4 CLINICAL PARTICULARS

4.1 THERAPEUTIC INDICATIONS

OMJJARA is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with moderate to severe anaemia who have primary myelofibrosis, post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis and who are Janus Kinase (JAK) inhibitor naïve or have been treated with ruxolitinib.

4.2 DOSE AND METHOD OF ADMINISTRATION

Adults

The recommended dosage of OMJJARA is 200 mg taken orally once daily. OMJJARA may be taken with or without food.

Missed dose

If a dose of OMJJARA is missed, the next scheduled dose should be taken the following day. Two doses should not be taken at the same time to make up for the missed dose.

Monitoring

Complete blood cell count and liver function tests must be performed before initiating treatment with OMJJARA, periodically during treatment, and as clinically indicated.

Dose modifications

Dose modifications should be considered for haematologic and nonhaematologic toxicities (Table 1).

Table 1 Dose modifications for adverse reactions

Haematologic toxicities		
Thrombocytopenia		Dose modification ^a
Baseline platelet count	Platelet count	
$\geq 100 \times 10^9/L$	$20 \times 10^9/L$ to $< 50 \times 10^9/L$	Reduce daily dose by 50 mg from the last given dose
	$< 20 \times 10^9/L$	Interrupt treatment until platelets recover to $50 \times 10^9/L$ Restart OMJJARA at a daily dose of 50 mg below the last given dose ^b
$\geq 50 \times 10^9/L$ to $< 100 \times 10^9/L$	$< 20 \times 10^9/L$	Interrupt treatment until platelets recover to $50 \times 10^9/L$ Restart OMJJARA at a daily dose of 50 mg below the last given dose ^b
$< 50 \times 10^9/L$	$< 20 \times 10^9/L$	Interrupt treatment until platelets recover to baseline Restart OMJJARA at a daily dose of 50 mg below the last given dose ^b
Neutropenia		Dose modification ^a
ANC $< 0.5 \times 10^9/L$		Interrupt treatment until ANC $\geq 0.75 \times 10^9/L$ Restart OMJJARA at a daily dose of 50 mg below the last given dose ^b
Nonhaematologic toxicities		
Hepatotoxicity (unless other apparent causes)		Dose modification ^a
ALT and/or AST $> 5 \times ULN$ (or $> 5 \times$ baseline, if baseline is abnormal) and/or total bilirubin $> 2 \times ULN$ (or $> 2 \times$ baseline, if baseline is abnormal)		Interrupt treatment until AST and ALT $\leq 2 \times ULN$ or baseline and total bilirubin $\leq 1.5 \times ULN$ or baseline Restart OMJJARA at a daily dose of 50 mg below the last given dose ^b If reoccurrence of ALT or AST elevations $> 5 \times ULN$, permanently discontinue OMJJARA
Other nonhaematologic		Dose modification ^a

Grade 3 or higher ^c Grade 2 or higher ^c bleeding	Interrupt treatment until the toxicity resolves to Grade 1 or lower (or baseline) Restart OMJJARA at a daily dose of 50 mg below the last given dose ^b
---	--

ANC = absolute neutrophil count; ALT = alanine transaminase; AST = aspartate transaminase;
ULN = upper limit of normal.

^a Reinitiate or escalate treatment up to starting dosage as clinically appropriate.

^b May reinitiate treatment at 100 mg if previously dosed at 100 mg.

^c Graded using the National Cancer Institute Common Terminology Criteria for Adverse Events per (CTCAE).

Treatment with OMJJARA should be discontinued in patients unable to tolerate 100 mg once daily.

Children

The safety and efficacy of OMJJARA in children and adolescents less than 18 years of age have not been established.

Elderly

No dose adjustment is required for patients who are aged 65 years and older (see section 5.2 PHARMACOKINETIC PROPERTIES, Special Patient Populations).

Renal impairment

No dose adjustment is required for patients with renal impairment (see section 5.2 PHARMACOKINETIC PROPERTIES, Special Patient Populations). OMJJARA has not been assessed in patients requiring dialysis.

Hepatic impairment

No dose adjustment is recommended for patients with mild or moderate hepatic impairment. The recommended starting dose of OMJJARA is 150 mg once daily in patients with severe hepatic impairment (Child-Pugh Class C) (see section 5.2 PHARMACOKINETIC PROPERTIES, Special Patient Populations).

4.3 CONTRAINDICATIONS

OMJJARA should not be used during pregnancy and breastfeeding.

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1 LIST OF EXCIPIENTS.

4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE

Infections

Infections, including serious and sometimes fatal bacterial and viral infections (including COVID-19), have occurred in patients treated with OMJJARA (see section 4.8 ADVERSE EFFECTS (UNDESIRABLE EFFECTS)). OMJJARA should not be initiated in patients with

active infections. Physicians should monitor patients receiving OMJJARA for signs and symptoms of infection and initiate appropriate treatment promptly.

Hepatitis B reactivation

Hepatitis B viral load (HBV-DNA titre) increases, with or without associated elevations in alanine transaminase (ALT) or aspartate transaminase (AST), have been reported in patients with chronic hepatitis B virus (HBV) infection taking JAK inhibitors, including OMJJARA. The effect of OMJJARA on viral replication in patients with chronic HBV infection is unknown. Patients with chronic HBV infection who receive OMJJARA should have their chronic HBV infection treated and monitored according to clinical HBV guidelines.

Thrombocytopenia and neutropenia

New onset of severe (Grade ≥ 3) thrombocytopenia and neutropenia was observed in patients treated with OMJJARA (see section 4.8 ADVERSE EFFECTS (UNDESIRABLE EFFECTS)). A complete blood count, including platelet count, should be obtained before initiating treatment with OMJJARA, periodically during treatment, and as clinically indicated. Dose interruption or reduction may be required (see 4.2 DOSE AND METHOD OF ADMINISTRATION, Dose modifications).

Major Adverse Cardiovascular Events (MACE)

In a large randomised active-controlled study of tofacitinib (another JAK inhibitor) in rheumatoid arthritis patients 50 years and older with at least one additional cardiovascular risk factor, a higher rate of MACE, defined as cardiovascular death, non-fatal myocardial infarction (MI) and non-fatal stroke, was observed with tofacitinib compared to tumour necrosis factor (TNF) inhibitors.

Events of MACE have been reported in patients receiving OMJJARA, however, a causal relationship has not been established. Prior to initiating or continuing therapy with OMJJARA, the benefits and risks for the individual patient should be considered particularly in patients 65 years of age and older, patients who are current or past long-time smokers, and patients with history of atherosclerotic cardiovascular disease or other cardiovascular risk factors.

Thrombosis

In a large randomised active-controlled study of tofacitinib (another JAK inhibitor) in rheumatoid arthritis patients 50 years and older with at least one additional cardiovascular risk factor, a dose dependent higher rate of venous thromboembolic events (VTE) including deep venous thrombosis (DVT) and pulmonary embolism (PE) was observed with tofacitinib compared to TNF inhibitors.

Events of DVT and PE have been reported in patients receiving OMJJARA. However, a causal association has not been established. In patients with myelofibrosis treated with OMJJARA in clinical trials, the rates of thromboembolic events were similar in OMJJARA and control-treated patients. Prior to initiating or continuing therapy with OMJJARA, the benefits and risks for the individual patient should be considered particularly in patients with cardiovascular risk factors (see section 4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE, Major Adverse Cardiovascular Events (MACE)).

Patients with symptoms of thrombosis should be promptly evaluated and treated appropriately.

Second primary malignancies

In a large randomised active controlled study of tofacitinib (another JAK inhibitor) in rheumatoid arthritis patients 50 years and older with at least one additional cardiovascular risk factor, a higher rate of malignancies, particularly lung cancer, lymphoma and non-melanoma skin cancer (NMSC) was observed with tofacitinib compared to TNF inhibitors. Lymphoma and other malignancies have been reported in patients receiving JAK inhibitors, including OMJJARA. However, a causal association has not been established.

Women of childbearing potential

Given uncertainties about whether OMJJARA may reduce the effectiveness of hormonal contraceptives, women using oral or other hormonal contraceptives should add a barrier method during treatment and for at least 1 week after the last dose of OMJJARA.

Use in hepatic impairment

See section 5.2 PHARMACOKINETIC PROPERTIES, Special Patient Populations.

Use in renal impairment

See section 5.2 PHARMACOKINETIC PROPERTIES, Special Patient Populations.

Use in the elderly

See section 5.2 PHARMACOKINETIC PROPERTIES, Special Patient Populations.

Paediatric use

The safety and efficacy of OMJJARA in children and adolescents less than 18 years of age has not been established.

Effects on laboratory tests

No data available.

4.5 INTERACTIONS WITH OTHER MEDICINES AND OTHER FORMS OF INTERACTIONS

Effect of other medicinal products on momelotinib

Effect of CYP inhibitors/inducers on momelotinib

Momelotinib undergoes metabolism through multiple CYP enzymes (including CYP3A4, CYP2C8, CYP2C9, CYP2C19, and CYP1A2), with CYP3A4 having the greatest contribution.

Strong CYP3A4 inducers

Coadministration of strong CYP3A4 inducers may lead to decreased exposure of OMJJARA and consequently a risk for reduced efficacy. Therefore, additional monitoring is recommended with concomitant use of OMJJARA and strong CYP3A4 inducers (including

but not limited to carbamazepine, phenobarbital, phenytoin, and St John's wort [*Hypericum perforatum*] (see section 5.2 PHARMACOKINETIC PROPERTIES).

Effect of transporters inhibitors/inducers on momelotinib

Momelotinib and its active metabolite, M21, are substrates of P-glycoprotein, BCRP, OATP1B1 and OATP1B3 transporters. Inhibitors or inducers of these transporters may potentially alter the systemic exposure of momelotinib and M21.

Effect of momelotinib on other medicinal products

Effect of momelotinib on CYP enzymes

In vitro studies indicate that momelotinib may inhibit CYP2B6 while M21 does not. Additionally, both momelotinib and M21 do not inhibit CYP1A2, CYP2C8, CYP2C9, CYP2C19, CYP2D6 or CYP3A4 *in vitro*. Furthermore, momelotinib and M21 do not induce CYP3A4 *in vitro*.

Effect of momelotinib on UGT enzymes

In vitro, momelotinib, but not M21, is an inhibitor of UGT1A1 and UGT1A9. Momelotinib and M21 are not inhibitors of UGT1A3, UGT1A4, UGT1A6 or UGT2B7.

Effect of momelotinib on drug transporters

Momelotinib is an inhibitor of BCRP, and M21 is an inhibitor of MATE1 *in vitro*. Momelotinib may increase the plasma concentration of medicinal products that are sensitive BCRP and MATE1 substrates; patients should be monitored for adverse reactions with co-administration.

In vitro, neither momelotinib nor M21 inhibits OAT1, OAT3 and OCT2 at clinically-relevant concentrations. Momelotinib and M21 have not been evaluated for MATE2-K inhibition.

Effect of momelotinib on hormonal contraceptives

It is currently unknown whether momelotinib may reduce the effectiveness of systemically acting hormonal contraceptives. Therefore, women using systemically acting hormonal contraceptives should add a barrier method during OMJJARA treatment and for at least 1 week after the last dose (see section 4.6 FERTILITY, PREGNANCY AND LACTATION).

4.6 FERTILITY, PREGNANCY AND LACTATION

Effects on fertility

There are no data on the effects of OMJJARA on human male or female fertility.

In male rats, momelotinib reduced sperm concentration and motility and reduced testes and seminal vesicle weights at oral doses ≥ 25 mg/kg/day (yielding 16-fold the plasma AUC for combined momelotinib and M21 [minimally produced in rats] in patients at the maximum recommended human dose [MRHD] of 200 mg), leading to reduced fertility at 68 mg/kg/day (44-fold the plasma AUC for combined momelotinib and M21 in patients at the MRHD).

Momelotinib impaired female fertility at oral doses of 68 mg/kg/day (yielding 59-fold the plasma AUC for combined momelotinib and M21 [minimally produced in rats] in patients at the MRHD), with reduction in the number of corpora lutea, oestrous cycles and implantation sites. Oral doses of ≥ 25 mg/kg/day (yielding 22-fold the plasma AUC for combined momelotinib and M21 in patients at the MRHD) caused adverse effects on early embryonic development (pre- and post-implantation loss, reduced number of live fetuses and total litter loss) in rats. Exposures at the no-observed-adverse-effect-level (NOAEL) in male and female rats at 5 mg/kg/day were approximately 3 times the recommended dose of 200 mg daily (based on combined momelotinib and M21 AUC).

Use in pregnancy

Pregnancy Category D

There are no data on the effects of OMJJARA in human pregnancy to inform a drug-associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes.

Embryofetal toxicity (embryonic death, visceral malformation, skeletal variations, and lower mean fetal body weights) was observed at oral maternal doses of 12 mg/kg (yielding exposure based on combined momelotinib and M21 [a major active human metabolite, minimally produced in rats] AUC 10-fold higher than in patients at the MRHD). Skeletal variations were observed (in the absence of maternal toxicity) at 6 mg/kg/day (resulting in exposures 3.5-fold higher than in patients at the MRHD based on combined momelotinib and M21 AUC). Abortion, reduced fetal weight and increased incidence of delayed ossification were observed in rabbits at 60 mg/kg/day (at exposures less than in patients at the MRHD based on combined momelotinib and M21 [minimally produced in rabbits] AUC), occurring in the context of maternotoxicity. No adverse effects on embryofetal development were observed in rats at 2 mg/kg/day and in rabbits at 30 mg/kg/day (exposures less than the exposure at the MRHD). In a pre- and postnatal development study in rats, momelotinib oral administration from organogenesis through lactation reduced the number of live pups at 12 mg/kg/day and lowered postnatal survival and offspring body weight at ≥ 6 mg/kg/day (at exposures less than in patients at the MRHD based on combined momelotinib and M21 AUC).

OMJJARA should not be used during pregnancy or by women attempting to become pregnant. Females of reproductive potential who are not pregnant should use highly effective contraception during therapy and for at least 1 week after the last dose of OMJJARA.

Use in lactation

There are no data on the presence of momelotinib and/or its metabolites in human milk. It is not known if momelotinib and/or its metabolites are excreted in human milk. Momelotinib was present in rat pups following nursing from treated dams (likely due to the presence of momelotinib in milk) with adverse effects in the offspring. A risk to the breastfed child cannot be excluded.

Patients should not breastfeed during treatment with OMJJARA and for at least 1 week after the last dose of OMJJARA.

4.7 EFFECTS ON ABILITY TO DRIVE AND USE MACHINES

There have been no studies to investigate the effect of OMJJARA on driving performance or the ability to operate machinery. However, patients who experience dizziness or blurred vision after taking OMJJARA should observe caution when driving or using machines (see section 4.8 ADVERSE EFFECTS (UNDESIRABLE EFFECTS)).

4.8 ADVERSE EFFECTS (UNDESIRABLE EFFECTS)

The safety of OMJJARA, based on three randomised, active-controlled, multicentre studies in adults with myelofibrosis (MOMENTUM, SIMPLIFY-1, SIMPLIFY-2), is presented in Table 2. Subjects were initially randomised to receive OMJJARA 200 mg once daily for 24 weeks (n = 448). The adverse reactions identified for OMJJARA are listed by body system organ class (SOC) and frequency.

Frequencies are defined as:

Very common: $\geq 1/10$

Common: $\geq 1/100$ to $< 1/10$

Uncommon: $\geq 1/1,000$ to $< 1/100$

Rare: $\geq 1/10,000$ to $< 1/1,000$

The most common severe adverse reaction (\geq Grade 3) was thrombocytopenia (12%). The most common adverse reaction leading to discontinuation of OMJJARA was thrombocytopenia (2.5%). The most common adverse reaction requiring dosage reduction and/or treatment interruption was thrombocytopenia (7%).

Table 2 Adverse reactions

MedDRA System Organ Class (SOC)	Frequency Category	Adverse Reaction	Frequency and Incidence Rate [n, (%)]
Infections and infestations	Very common	Infections ^a	177 (39.5)
Blood and lymphatic system disorders	Very common	Thrombocytopenia ^b	94 (21.0)
	Common	Neutropenia ^c	26 (5.8)
Metabolism and nutrition disorders	Common	Vitamin B1 deficiency	14 (3.1)
Nervous system disorders	Very common	Dizziness	58 (12.9)
		Headache	60 (13.4)
	Common	Syncope	8 (1.8)
		Peripheral neuropathy ^d	39 (8.7)
Eye disorders	Common	Blurred vision	12 (2.7)
Ear and labyrinth disorders	Common	Vertigo	10 (2.2)
Vascular disorders	Common	Hypotension	27 (6)
		Haematoma	10 (2.2)
		Flushing	15 (3.3)

Respiratory, thoracic and mediastinal disorders	Very common	Cough	45 (10)
Gastrointestinal disorders	Very common	Diarrhoea Abdominal pain Nausea	102 (22.8) 48 (10.7) 75 (16.7)
	Common	Vomiting Constipation	36 (8) 43 (9.6)
Skin and subcutaneous tissue disorders	Common	Rash	25 (5.6)
Musculoskeletal and connective tissue disorders	Common	Arthralgia	34 (7.6)
		Pain in extremity	24 (5.4)
General disorders and administration site conditions	Very common	Asthenia Fatigue	49 (10.9) 55 (12.3)
	Common	Pyrexia	41 (9.2)
Investigations	Common	Alanine transaminase (ALT) increased	21 (4.7)
		Aspartate transaminase (AST) increased	16 (3.6)
Injury, poisoning and procedural complications	Common	Contusion	26 (5.8)

^a Infections includes the preferred terms of the Infections and Infestations SOC such as urinary tract infection, upper respiratory tract infection, COVID-19, herpes zoster; excludes opportunistic infections.

^b Thrombocytopenia includes platelet count decreased.

^c Neutropenia includes neutrophil count decreased.

^d Peripheral neuropathy includes peripheral sensory neuropathy, peripheral motor neuropathy, neuropathy peripheral, peripheral sensorimotor neuropathy, neuralgia, and polyneuropathy.

^e Rash includes rash maculo-papular, rash erythematous, drug eruption, rash follicular, rash macular, and rash pustular

Infections

In the three randomised clinical studies, 40% (178/448) of patients treated with OMJJARA experienced an infection. The most common infections ($\geq 2\%$) were urinary tract infection (6%), upper respiratory tract infection (5%), pneumonia (3.6%), nasopharyngitis (2.9%), COVID-19 (2.7%), cystitis (2.7%), bronchitis (2.5%), and oral herpes (2.5%). The majority of infections were mild or moderate, while 10% (47/448) of patients experienced a severe infection (\geq Grade 3). The proportion of patients discontinuing treatment due to an infection was 2% (9/448). Fatal infections were reported in 2.2% (10/448) of patients. In the individual studies of MOMENTUM, SIMPLIFY-1, and SIMPLIFY-2, the rates of infections for OMJJARA were 34%, 36%, and 55%, respectively, compared with 35% for danazol, 43% for ruxolitinib, and 42% for best available therapy.

Thrombocytopenia

In the three randomised clinical studies, 21% (94/448) of patients treated with OMJJARA experienced thrombocytopenia; 12% (54/448) of patients treated with OMJJARA experienced severe thrombocytopenia (\geq Grade 3). The proportion of patients discontinuing treatment due to thrombocytopenia was 2.5% (11/448). In the individual studies of MOMENTUM, SIMPLIFY-1, and SIMPLIFY-2, the rates of thrombocytopenia for OMJJARA were 28%, 19%, and 17%, respectively, compared with 15% for danazol, 29% for ruxolitinib, and 12% for best available therapy.

Elevated ALT/AST

In the three randomised clinical trials, new or worsening elevations of ALT and AST (all grades) occurred in 20% (88/448) and 20% (90/448), respectively, of patients treated with OMJJARA; Grade 3 and 4 transaminase elevations occurred in 1.1% (5/448) and 0.2% (1/448) of patients, respectively. Reversible drug-induced liver injury has been reported in patients with myelofibrosis treated with OMJJARA in clinical trials.

Post-marketing data

As these post-marketing events were reported from a population of unknown size, the frequency is unknown.

Immune system disorders

Hypersensitivity

Skin and subcutaneous tissue disorders

Rash: Cases of rash requiring hospitalisation have been reported.

Erythema multiforme

Reporting suspected adverse effects

Reporting suspected adverse reactions after registration of the medicinal product is important. It allows continued monitoring of the benefit-risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions at www.tga.gov.au/reporting-problems.

4.9 OVERDOSE

There is currently limited experience of overdosage with OMJJARA. If overdose is suspected, the patient should be monitored for any signs or symptoms of adverse reactions or effects, and appropriate standard of care measures should be instituted immediately. Further management should be as clinically indicated or as recommended by the national poisons centre, where available.

For information on the management of overdose, contact the Poisons Information Centre on 13 11 26 (Australia).

5 PHARMACOLOGICAL PROPERTIES

5.1 PHARMACODYNAMIC PROPERTIES

Mechanism of action

Myelofibrosis is a myeloproliferative neoplasm associated with constitutive activation and dysregulated Janus Kinase (JAK) signalling that contributes to elevated inflammation and hyperactivation of activin A receptor type 1 (ACVR1), also known as activin receptor-like kinase 2 (ALK2). Momelotinib and its major circulating metabolite (M21) are inhibitors of wild type Janus Kinase 1 and 2 (JAK1/JAK2) and mutant JAK2^{V617F}, which contribute to signalling of a number of cytokines and growth factors that are important for haematopoiesis and immune function. JAK1 and JAK2 recruit and activate STAT (signal transducer and activator of transcription) proteins that control gene transcription impacting inflammation, haematopoiesis, and immune regulation. Momelotinib and its major human circulating metabolite, M21, additionally inhibit ACVR1 which subsequently down regulates liver hepcidin expression resulting in increased iron availability and red blood cell production. Momelotinib and M21 potentially inhibit additional kinases, such as other JAK family members, IκB kinase (IKK), interleukin-1 receptor-associated kinase 1 (IRAK1), and others.

Pharmacodynamic effects

OMJJARA inhibits cytokine-induced STAT3 phosphorylation in whole blood from patients with myelofibrosis. Maximal inhibition of STAT3 phosphorylation occurred 2 hours after OMJJARA dosing with inhibition persisting for at least 6 hours. OMJJARA also demonstrated both acute and prolonged reduction of circulating hepcidin in patients with myelofibrosis, resulting in increased iron availability and erythropoiesis.

Cardiovascular effects

At a dose of 4 times the highest recommended starting dosage of 200 mg, OMJJARA did not prolong the QT interval to any clinically relevant extent.

Clinical trials

The efficacy of OMJJARA in the treatment of patients with intermediate-1, intermediate-2, or high-risk myelofibrosis, including primary myelofibrosis, post-polycythaemia vera (post-PV) myelofibrosis or post-essential thrombocythaemia (post-ET) myelofibrosis, was established in two randomised, active-controlled Phase 3 studies, MOMENTUM and SIMPLIFY-1. All patients received a starting dose of OMJJARA 200 mg once daily, irrespective of their baseline platelet count (in MOMENTUM study, the minimum platelet count was $25 \times 10^9/L$; in SIMPLIFY 1 study, the minimum platelet count was $50 \times 10^9/L$).

MOMENTUM

Myelofibrosis patients who have been treated with ruxolitinib

MOMENTUM was a double-blind, 2:1 randomised, active-controlled study in 195 symptomatic and anaemic patients with myelofibrosis who had previously received a JAK inhibitor. The median age was 71 years (range 38 to 86 years); 79% were 65 years or older and 63% were male. Sixty-four percent (64%) of patients had primary myelofibrosis, 19% had post-PV myelofibrosis, and 17% had post-ET myelofibrosis. Five percent (5%) of patients had intermediate-1 risk, 57% had intermediate-2 risk, and 35% had high-risk

disease. Patients were symptomatic with a Myelofibrosis Symptom Assessment Form (MFSAF) v4.0 total symptom score (TSS) of ≥ 10 at screening (mean MFSAF TSS 27 at baseline), and anaemic with haemoglobin (Hgb) < 10 g/dL. The MFSAF daily diary captured the core symptoms of myelofibrosis: night sweats, abdominal discomfort, pain under the left rib, fatigue/tiredness, early satiety, pruritus, and bone pain. Within the 8 weeks prior to enrolment, 79% had red blood cell transfusions. At baseline, 13% and 15% of patients were transfusion independent in the OMJJARA and danazol groups, respectively. The baseline median Hgb was 8 g/dL and the median platelet count was $96 \times 10^9/L$. The baseline median palpable spleen length was 11.0 cm below the left costal margin; the median spleen volume [measured by magnetic resonance imaging (MRI) or computed tomography (CT)] was 2105 cm³ (range 610 to 9717 cm³).

Patients were treated with OMJJARA 200 mg once daily or danazol 300 mg twice daily for 24 weeks, followed by open-label treatment with OMJJARA. The two primary efficacy endpoints were percentage of patients with total symptom score (TSS) reduction of 50% or greater from baseline to week 24 (as measured by the Myelofibrosis Symptom Assessment Form [MFSAF] v4.0), and the percentage of patients who were transfusion independent (TI) at week 24 (defined as no transfusions and all haemoglobin values ≥ 8 g/dL in the 12 weeks prior to week 24).

The efficacy of OMJJARA in the treatment of patients with primary or secondary myelofibrosis and anaemia was established based on a significantly higher percentage of patients treated with OMJJARA compared to danazol, achieving a MFSAF v4.0 Total Symptom Score reduction of 50% or more at Week 24 compared with their own baseline score and by establishing non-inferiority of OMJJARA with danazol in transfusion independence in the last 12 weeks of randomised treatment.

A key secondary endpoint measured the percentage of subjects with $\geq 35\%$ reduction in spleen volume from baseline at week 24. At Week 24, a significantly higher percentage of patients treated with OMJJARA achieved a spleen volume reduction by 35% or greater from baseline (Table 4).

Table 4 Efficacy Results of Patients Achieving Symptom Reduction, Transfusion Independence, and Spleen Volume Reduction at Week 24 (MOMENTUM)

	OMJJARA n = 130	Danazol n = 65	p-value
	n %	n %	
Patients with Total Symptom Score Reduction of 50% or greater	32 25%	6 9%	0.0095
Treatment Difference (95% CI)	16% (6, 26)		
Patients with Transfusion Independence ^a	39 30%	13 20%	0.0116
Non-inferiority Treatment Difference ^b (95% CI)	14% (2, 25)		
Patients with Spleen Volume Reduction by 25% or greater	51 39%	4 6%	<0.0001
Treatment Difference (95% CI)	33% (23, 44)		
Patients with Spleen Volume Reduction by 35% or greater	29 22%	2 3%	0.0011
Treatment Difference (95% CI)	18% (10, 27)		
Patients with No Transfusion ^c	46 35%	11 17%	0.0012
Treatment Difference (95% CI)	17% (8, 26)		
	LS Mean^d	LS Mean^d	0.0014
Change from baseline in Total Symptom Score	-9.4	-3.1	
Treatment Difference (95% CI)	-6.22 (-10.0, -2.43)		

CI = confidence interval; LS = least square.

^a Defined as no transfusions and all Hgb values ≥ 8 g/dL in the 12 weeks prior to Week 24.

^b Non-inferiority difference between OMJJARA response rate and 80% of danazol response rate; 1-sided p-value.

^c Percentage of patients with zero red blood cell or whole blood units transfused during the 24-week treatment period.

^d Least square mean and difference at Week 24 based on a longitudinal mixed effect model for continuous Total Symptom Score change from baseline on a 70-point scale.

SIMPLIFY-1

Myelofibrosis patients who are JAK inhibitor naïve

SIMPLIFY-1 was a double-blind, randomised, active-controlled study in 432 patients with myelofibrosis who had not previously received a JAK inhibitor. The median age was 66 years (range 25 to 86 years) with 57% of patients older than 65 years and 56% male. Fifty-six percent (56%) of patients had primary myelofibrosis, 23% had post-PV myelofibrosis, and 21% had post-ET myelofibrosis. Twenty-one percent (21%) of patients had intermediate-1 risk, 33% had intermediate-2 risk, and 46% had high-risk disease. TSS response was measured by the modified Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF) v2.0 diary (mean TSS 19 at baseline). The MPN-SAF daily diary captured the core symptoms of myelofibrosis: night sweats, abdominal discomfort, pain under the left rib, fatigue/tiredness, early satiety, pruritus, and bone pain. Within the 8 weeks

prior to enrolment, 25% of patients had red blood cell transfusions. The baseline median Hgb was 10.4 g/dL and the median platelet count was $243.0 \times 10^9/L$ at baseline. The baseline median palpable spleen length was 12.0 cm below the left costal margin; the median spleen volume (measured by MRI or CT) was 1916 cm³ (range 206 to 9022 cm³).

Patients were treated with OMJJARA 200 mg or ruxolitinib adjusted dose twice daily for 24 weeks, followed by open-label treatment with OMJJARA without tapering of ruxolitinib. The primary efficacy endpoint was percentage of patients with spleen volume response (reduction by 35% or greater) at Week 24; analyses were also conducted in a subset of patients with moderate to severe anaemia (Hgb < 10 g/dL) (Table 5). A similar percentage of patients treated with OMJJARA or ruxolitinib achieved a spleen volume response in both populations. Other endpoints included TSS response and red blood cell transfusion requirements. Non-inferiority of OMJJARA with ruxolitinib was not demonstrated for the first of the secondary endpoints, TSS reduction of 50% or greater.

Table 5 Percent of Overall Patients and Anaemic Patients Achieving Symptom Reduction, Spleen Volume Reduction, and Transfusion Independence at Week 24 (SIMPLIFY-1)

	Overall Population		Anaemic Population (Hgb <10 g/dL)	
	OMJJARA n = 215	Ruxolitinib n = 217	OMJJARA n = 86	Ruxolitinib n = 95
	n %	n %	n %	n %
Patients with Spleen Volume Reduction by 35% or greater	57 27%	64 29%	27 31%	31 33%
Non-inferiority Treatment Difference ^a (95% CI) p value	9% (2, 16) p = 0.014		—	
Patients with Total Symptom Score Reduction of 50% or greater	60/211 28%	89/211 42%	21/84 25%	33/93 35%
Non-inferiority Treatment Difference ^b (95% CI) p value	0% (-8, 8) p = 0.98		—	
Patients with Transfusion Independence ^c	143 67%	107 49%	40 47%	25 26%
Treatment Difference (95% CI) p value	18% (9, 26) p < 0.001 ^d		—	

CI = confidence interval.

^a Non-inferiority difference between OMJJARA rate and 60% of ruxolitinib response rate.

^b Non-inferiority difference between OMJJARA rate and 67% of ruxolitinib response rate.

^c Defined as no transfusions and all Hgb values ≥ 8 g/dL in the 12 weeks prior to Week 24.

^d Nominal p value.

5.2 PHARMACOKINETIC PROPERTIES

Absorption

Momelotinib is rapidly absorbed after oral administration with the maximal plasma concentration (C_{max}) achieved within 3 hours post-dose, with plasma exposures increased in a less than dose proportional manner, especially at doses above 300 mg. At the dose of 200 mg once daily at steady state, the mean (%CV) momelotinib C_{max} is 479 ng/mL (61%) and AUC_{tau} is 3288 ng•h/mL (60%) in patients with myelofibrosis.

Following low-fat and high-fat meals in healthy volunteers, the C_{max} of momelotinib was 38% and 28% higher, respectively, and the AUC was 16% and 28% higher, respectively, as compared with those under fasting conditions. These changes in exposure were not clinically meaningful.

Distribution

Plasma protein binding of momelotinib is approximately 91% in human. The mean apparent volume of distribution of momelotinib at steady-state was 984 L in patients with myelofibrosis receiving momelotinib 200 mg daily suggesting extensive tissue distribution.

Metabolism

Human metabolism of momelotinib is predominantly mediated by CYP enzymes with contributions in the following order: CYP3A4 (36%), CYP2C8 (19%), CYP2C19 (19%), CYP2C9 (17%), and CYP1A2 (9%). M21 is an active human metabolite that has approximately 40% of the pharmacological activity of the parent. M21 is formed by CYP followed by aldehyde oxidase metabolism of momelotinib. The mean M21 to momelotinib ratio for AUC ranged from 1.4 to 2.1.

Excretion

Following an oral dose of momelotinib 200 mg, the mean terminal half-life ($t_{1/2}$) of momelotinib was 4 to 8 hours; the half-life of M21 is similar. The apparent total clearance (CL/F) of momelotinib was 103 L/h in patients with myelofibrosis.

Momelotinib is mainly eliminated through metabolism and then excreted to faeces. Following a single oral dose of [14 C]-labelled momelotinib in healthy male subjects, 69% of radioactivity was excreted in the faeces (13% of dose as unchanged momelotinib), and 28% in the urine (<1% of dose as unchanged momelotinib).

Special patient populations

Renal impairment

Momelotinib AUC decreased by 13% in subjects with moderate renal impairment (eGFR 30-59 mL/min/1.73 m²) and AUC decreased by 16% in subjects with severe renal impairment (eGFR 15-29 mL/min/1.73 m²) compared to subjects with normal renal function (eGFR \geq 90 mL/min/1.73 m²). The AUC of the active metabolite, M21, increased by 20% and 41%, respectively, in subjects with moderate and severe renal impairment compared to subjects with normal renal function. There are no data in patients with end-stage renal disease (ESRD) receiving dialysis.

Hepatic impairment

Momelotinib AUC increased by 8% and 97% in subjects with moderate (Child-Pugh Class B) and severe (Child-Pugh Class C) hepatic impairment, respectively, compared to subjects with normal hepatic function (see section 4.2 DOSE AND METHOD OF ADMINISTRATION).

Age, gender, race, and bodyweight

Age, gender, race, or weight do not have a clinically meaningful effect on the pharmacokinetics of momelotinib based on a population pharmacokinetic analysis.

5.3 PRECLINICAL SAFETY DATA

Genotoxicity

Momelotinib was not mutagenic in a bacterial reverse mutation assay or clastogenic in an *in vitro* chromosomal aberration assay with human peripheral blood lymphocytes or *in vivo* in a rat bone marrow micronucleus assay.

Carcinogenicity

The carcinogenic potential of momelotinib was assessed in a 6-month rasH2 transgenic mouse study and a 2-year rat carcinogenicity study, both conducted by the oral route.

Momelotinib was not carcinogenic in transgenic mice up to the highest dose level tested (100 mg/kg/day, yielding exposure levels based on combined momelotinib and M21 [a major active human metabolite, minimally produced in mice] AUC 12-times the MRHD).

Increased incidence of testicular interstitial (Leydig) cell adenoma was noted in rats at a dose of 15 mg/kg/day (approximately 15-times the exposure based on combined momelotinib and M21 [minimally produced in rats] AUC at the MRHD). The increase in Leydig cell adenomas is considered to be a species-specific effect secondary to the induction of the prolactin signalling pathway, and, therefore, does not constitute a clinical carcinogenic risk.

6 PHARMACEUTICAL PARTICULARS

6.1 LIST OF EXCIPIENTS

Microcrystalline cellulose
Lactose monohydrate
Sodium starch glycolate (type A)
Magnesium stearate
Colloidal anhydrous silica
Propyl gallate
Polyvinyl alcohol
Macrogol 3350
Titanium dioxide
Purified talc
Iron oxide yellow
Iron oxide red

6.2 INCOMPATIBILITIES

Incompatibilities were not identified as part of the registration of this medicine.

6.3 SHELF LIFE

In Australia, information on the shelf life can be found on the public summary of the Australian Register of Therapeutic Goods (ARTG). The expiry date can be found on the packaging.

6.4 SPECIAL PRECAUTIONS FOR STORAGE

Store below 30°C.

Store in the original bottle to protect from moisture. Do not remove the desiccant.

6.5 NATURE AND CONTENTS OF CONTAINER

White, high-density polyethylene (HDPE) bottles with child-resistant polypropylene cap and induction-sealed, aluminium faced liner. Each bottle contains 30 film-coated tablets, silica gel desiccant, and polyester coil packing material.

Not all strengths, dose forms, pack sizes, container types may be distributed in Australia.

6.6 SPECIAL PRECAUTIONS FOR DISPOSAL

In Australia, any unused medicine or waste material should be disposed of by taking to your local pharmacy.

6.7 PHYSICOCHEMICAL PROPERTIES


Momelotinib dihydrochloride monohydrate is a light yellow to brown to reddish-brown solid, very slightly soluble to practically insoluble in water across the physiological pH range. The IUPAC chemical name is N-(cyanomethyl)-4-(2-([4-(morpholin-4-yl)phenyl]amino)pyrimidin-4-yl)benzamide dihydrochloride hydrate.

Molecular Formula

$C_{23}H_{22}N_6O_2 \cdot 2HCl \cdot H_2O$

$C_{23}H_{22}N_6O_2$ (free base)

Chemical structure



Relative Molecular Mass

Momelotinib dihydrochloride monohydrate = 505.40

Momelotinib (free base) = 414.47

CAS number

Momelotinib dihydrochloride monohydrate: 1841094-17-4

Momelotinib (free base): 1056634-68-4

7 MEDICINE SCHEDULE (POISONS STANDARD)

Schedule 4 – Prescription Only Medicine

8 SPONSOR

GlaxoSmithKline Australia Pty Ltd

Level 4, 436 Johnston Street,

Abbotsford, Victoria, 3067

Phone: 1800 033 109

www.gsk.com.au

9 DATE OF FIRST APPROVAL

18 December 2024

10 DATE OF REVISION

3 February 2026

SUMMARY TABLE OF CHANGES

Section Changed	Summary of new information
4.8	Inclusion of 'Hypersensitivity' and 'Erythema multiforme' in the post-marketing data

Version 2.0

Trade marks are owned by or licensed to the GSK group of companies.

© 2026 GSK group of companies or its licensor.